文献速递贫血与红细胞疾病

抑制血红素加氧酶改善β-地中海贫血小鼠模型的贫血并减少铁过载

Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.
PubMed 文献 · Blood · 2017-11-27

研究在β-地中海贫血中间型小鼠模型Th3/+中,用锡原卟啉IX(SnPP)抑制血红素加氧酶(HO),观察到肝脏血红素铁再循环减少、贫血改善,促红细胞生成素下降、铁调素血清水平升高,伴无效造血减轻;骨髓血红素分解代谢和铁释放减少、凋亡减少。作者认为HO活性所致血红素释铁参与地中海贫血病理,抑制血红素分解代谢的新疗法可能有益。

要点

  • SnPP抑制HO可改善Th3/+小鼠贫血并减少肝脏血红素铁再循环。
  • SnPP使Th3/+小鼠血清促红细胞生成素下降、铁调素升高,伴无效造血减轻。
  • SnPP治疗Th3/+小鼠骨髓血红素分解代谢和铁释放减少、凋亡减少。

核心结论

  • HO活性所致血红素释铁参与地中海贫血病理生理,抑制血红素分解代谢的新疗法可能有益于改善地中海贫血的贫血和无效造血。

研究设计与样本

  • 研究利用β-地中海贫血中间型小鼠模型Th3/+,以锡原卟啉IX(SnPP)抑制血红素加氧酶(HO)进行实验。

主要发现

  • SnPP抑制HO使Th3/+小鼠肝脏血红素铁再循环减少并改善贫血。
  • SnPP给药使Th3/+小鼠血清促红细胞生成素下降、铁调素升高,伴无效造血减轻。
  • SnPP治疗的Th3/+小鼠骨髓显示血红素分解代谢减少、铁释放减少及凋亡减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thalassemias are a heterogeneous group of red blood cell disorders, considered a major cause of morbidity and mortality among genetic diseases. However, there is still no universally available cure for thalassemias. The underlying basis of thalassemia pathology is the premature apoptotic destruction of erythroblasts causing ineffective erythropoiesis. In β-thalassemia, β-globin synthesis is reduced causing α-globin accumulation. Unpaired globin chains, with heme attached to them, accumulate in thalassemic erythroblasts causing oxidative stress and the premature cell death. We hypothesize that in β-thalassemia heme oxygenase (HO) 1 could play a pathogenic role in the development of anemia and ineffective erythropoiesis. To test this hypothesis, we exploited a mouse model of β-thalassemia intermedia, Th3/+ We observed that HO inhibition using tin protoporphyrin IX (SnPP) decreased heme-iron recycling in the liver and ameliorated anemia in the Th3/+ mice. SnPP administration led to a decrease in erythropoietin and increase in hepcidin serum levels, changes that were accompanied by an alleviation of ineffective erythropoiesis in Th3/+ mice. Additionally, the bone marrow from Th3/+ mice treated with SnPP exhibited decreased heme catabolism and diminished iron release as well as reduced apoptosis. Our results indicate that the iron released from heme because of HO activity contributes to the pathophysiology of thalassemia. Therefore, new therapies that suppress heme catabolism may be beneficial in ameliorating the anemia and ineffective erythropoiesis in thalassemias.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Garcia-Santos D, Hamdi A, Saxova Z, et al. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model. Blood. 2017. PMID: 29180398. doi:10.1182/blood-2017-07-798728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。